(Circulation. 2001;103:1631.)
© 2001 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Department of Cardiology, Skejby Hospital (H.E.B., J.F.L., H.W., P.S., W.Y.K., M.B., L.T., A.K.P.), and the PET Center, Aarhus Kommunehospital (F.H.), University Hospital, Aarhus, Denmark.
Correspondence to Hans Erik Bøtker, MD, PhD, Department of Cardiology, Skejby Hospital, University Hospital in Aarhus, Brendstrupgaardsvej, DK-8200 Aarhus N, Denmark. E-mail heb{at}dadlnet.dk
| Abstract |
|---|
|
|
|---|
Methods and ResultsUnipolar voltage amplitudes and local endocardial shortening were measured in 31 patients (mean±SD age, 62±8 years) with ischemic cardiomyopathy (ejection fraction, 30±9%). Dysfunctional regions, identified by 3D echocardiography, were characterized as nonviable when PET revealed matched reduction of perfusion and metabolism and as viable when perfusion was reduced or normal and metabolism was preserved. Mean unipolar voltage amplitudes and local shortening differed among normal, nonviable, and viable dysfunctional segments. Coefficient of variation for local shortening exceeded differences between groups and did not allow distinction between normal and dysfunctional myocardium. Optimum nominal discriminatory unipolar voltage amplitude between nonviable and viable dysfunctional myocardium was 6.5 mV, but we observed a great overlap between groups. Individual cutoff levels calculated as a percentage of electrical activity in normal segments were more accurate in the detection of viable dysfunctional myocardium than a general nominal cutoff level. The optimum normalized discriminatory value was 68%. Sensitivity and specificity were 78% for the normalized discriminatory value compared with 69% for the nominal value (P<0.02).
ConclusionsEndocardial ECG amplitudes in patients with ischemic cardiomyopathy display a wide scatter, complicating the establishment of exact nominal values that allow distinction between viable and nonviable areas. Individual normalization of unipolar voltage amplitudes improves diagnostic accuracy. Electroanatomic mapping may enable identification of myocardial viability.
Key Words: electrocardiography electrophysiology endocardium hibernation infarction
| Introduction |
|---|
|
|
|---|
We evaluated whether LV electromechanical mapping data can distinguish between viable and nonviable myocardial dysfunction in patients with severe LV dysfunction caused by ischemic heart disease by comparison with 3D echocardiography and perfusion and metabolism data obtained with PET.
| Methods |
|---|
|
|
|---|
Study Protocol
The patients underwent 3D
echocardiography to characterize wall motion as
either normal or dysfunctional. Subsequently,
[13N]ammonia and
[18F]fluorodeoxyglucose (FDG) PET were
used to determine whether dysfunctional regions were nonviable or
viable.
We studied reproducibility of electromechanical variables in a subgroup of 10 men (age, 59±12 years; ejection fraction, 30±12%). After finishing the electromechanical map, we sampled another 10 (true) duplicate measurements from representative parts of the myocardium identified as normal or dysfunctional by the color code from the 3D map. Each point was registered twice with the same catheter tip position. Furthermore, 10 pairs of points within a 5-mm distance from each other were identified randomly scattered over the myocardium (simulated duplicate measurements).
Echocardiography
We performed transthoracic 3D
echocardiography with tissue harmonic imaging using
a 2.5-MHz transducer mounted in a handheld rotation device (Vingmed
System Five, GE-Vingmed Ultrasound). Coaxial rotation from the apical
position was obtained with ECG-triggered recording in which
each R wave initiated a 30° stepwise rotation of the transducer. A
total of six 30° rotations covered the entire LV. The resulting 2D
images were stored as digital cine loops in a computer for offline
analysis and generation of a 3D image (Echo-Pac software,
GE-Vingmed Ultrasound). From the 3D image, regional wall motion scoring
was evaluated semiquantitatively as normal or dysfunctional with the
9-segment model.9 LV volumes
were calculated with all 6 sections according to a volume estimation
algorithm based on calculation of reconstructed polyhedrons as recently
described.10 The first image
after the R wave of the ECG was defined as end diastole;
the smallest area just before mitral valve opening was defined as end
systole.
PET Studies
The PET studies were conducted under a
hyperinsulinemic, euglycemic (5
mmol/L) clamp (Actrapid, Novo Nordisk) 40 mU ·
min-1 · m-2
body surface area starting 1.5 hours before the FDG scan. All
subjects were scanned in 2D with an ECAT EXACT HR whole-body scanner
(CTI/Siemens) with an axial field of view of 15 cm. A 9-minute emission
scan was made 10 minutes after injection of 740 MBq
[13N]NH3. A
15-minute transmission scan was then acquired. Fifty minutes after
injection of
[13N]NH3, 370 MBq
FDG was injected, and 50 minutes later, a static 10-minute frame was
acquired. The emission scans were corrected for scatter and
attenuation. The images were reconstructed using back-projected
filtering and a Hann filter with a cutoff frequency of 0.2 sinogram
element, resulting in a spatial resolution of 9 mm. The images
were resliced into 12 equally spaced short-axis images from apex to the
aortic outlet. Circular regions of interest (ROIs) were defined on each
short-axis plane. The ROIs were 4 pixels (7 mm) wide. Nine ROIs
were defined to match the echocardiographic and
electromechanical ROIs. The
[13N]NH3 images
were scaled so that the average activity was 1 in the ROI with maximal
average activity. The FDG image was scaled to give the average value of
1 in this ROI. Segments with normal contractility on
echocardiography were classified as normal.
Segments with abnormal contractility on
echocardiography were classified as nonviable when
PET showed a matched reduction of perfusion and metabolism
(scaled average
[13N]NH3 <0.8 and
scaled average FDG <0.7) and as viable when PET showed preserved
metabolism (scaled average FDG >0.7) in the presence of
preserved (scaled average
[13N]NH3
0.8) or
reduced flow (scaled average
[13N]NH3
<0.8).
Mapping System
The electromechanical mapping system has been
described in detail
previously.1 2 The
main components are (1) a triangular location pad with 3 coils placed
under the patient table generating ultralow magnetic field energy, (2)
a stationary reference catheter with a small magnetic field sensor
located at the body surface, (3) a navigation sensor mapping catheter
(7F) with deflectable tip and electrodes providing endocardial signals,
and (4) a Silicon Graphics workstation for data processing and 3D
reconstruction.
Mapping Procedure
The patients were given heparin (100 U/kg). We used
either a direct retrograde left-sided approach through the femoral
artery (n=8) or a transseptal approach through the femoral vein (n=23).
Transseptal catheterization was conducted with a
Mullins transseptal sheath and dilator and a Brokenbrough needle. The
mapping catheter was advanced under fluoroscopic guidance to the LV.
Points outlining the LV boundaries (apex, aortic outflow, mitral
inflow) were acquired with fluoroscopic guidance. These hallmarks
minimized rotational and horizontal misalignment in the construction of
the polar maps that were used for comparison between the different
imaging modalities. We acquired points only when the catheter tip was
stable on the endocardium using location stability, loop stability, and
cycle length stability as specified by the
manufacturer.1 2
The system uses a triangular algorithm to reconstruct the LV
anatomy, which is presented in real time on the
workstation
(Figure 1
). Once all endocardial segments were
represented with
3 and on average 6 points on the map,
the operator completed the reconstruction of the LV map, and the
catheter was removed from the LV. Subsequently, automatic editing was
performed to remove internal points and points with unsatisfactory
stability with moderate filtering.
|
Electromechanical Data
From the mechanical data, regional
contractility was obtained by the use of the linear
endocardial local shortening (LS) formula:
LS(p)=
[Li(ED)-Li(ES)/Li(ED)]x100,
where LS(p) denotes the weighted average LS of a point (p) relative to
all its endocardial neighboring points, and
Li(ED) and Li(ES) are the
distances of an index point from its neighbors at end
diastole and end systole, respectively. The LS(p) value is
a ratio that becomes smaller or even negative if regional
contractility is reduced or becomes paradoxical. From
the electrical data, a color-coded unipolar voltage map was
generated.
A fixed polar reference coordinate map was defined with anatomic reference points acquired at end diastole to match the echocardiographic and PET ROIs. The center of mass of the reconstructed LV chamber was automatically calculated by the system from the set of endocardial points sampled. The long axis of the LV was defined as the line connecting the apex (the most distal point from the center of mass) and the center of mass. The long axis was divided into 3 segments: apex, midventricle, and base, consisting of 20%, 40%, and 40% of the long axis, respectively. The midventricular and base segments were further divided into 4 regions: anterior, septal, inferoposterior, and lateral. Consequently, endocardial sites were divided into a total of 9 segments for comparative analysis with echocardiographic and PET imaging data.
End-diastolic and end-systolic volumes were calculated as the maximal and minimal volumes throughout the cardiac cycle.11
Statistical Analysis
Data are presented as mean±SD unless
otherwise indicated. Means of nominal values (voltage and LS) were
compared between myocardial segments classified as normal, nonviable,
or viable by ANOVA. When appropriate, a post hoc pair-wise comparison
was made with the Bonferroni modification. Normalized voltage
amplitudes were obtained as the percentage of the mean value of all
normal segments in each patient. To estimate the contribution of
between- and within-subject variation to total variation, we used
nested 2-way ANOVA. The components of variation were compared with an F
test. Data were expressed as coefficients of variation (CVs),
calculated by dividing the square root of the variances with the great
means. The critical difference (CD) was
calculated as follows:
![]() |
The diagnostic performance of nominal and normalized unipolar voltage amplitudes for discrimination between nonviable and viable myocardial dysfunction was analyzed by receiver-operating characteristic (ROC) curve analysis12 comparing nominal and normalized voltage amplitudes to distinguish between nonviable and viable myocardial dysfunction. Correlation was sought through Spearmans test, and comparisons between 2 groups were made with a t test. A value of P<0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
|
Procedural Characteristics
We sampled 73±19 points, of which 56±14 points
fulfilled stability criteria for construction of the LV map. Of 279
myocardial segments, 272 were available for comparative
analysis. In 7 segments, no definite interpretation could be
made because too few (<3) points were sampled during the mapping
procedure. Mapping time was 43±11 minutes.
Local Contractile Function
Figure 2
shows contractile function, LS, in segments with
normal function and in dysfunctional segments classified as nonviable
or viable. On average, normal segments had higher values (10.1±5%)
than dysfunctional segments. Nonviable segments had lower values
(3.2±3.8%) than viable segments (5.6±3.9%), but we found
considerable overlap between normal and dysfunctional segments.
However, visual inspection of the color-coded maps helped us identify
regions with abnormal contractility
(Figure 1
). We found no regional differences in LS within
normal, nonviable, or viable segments
(Table 1
).
|
Analysis of reproducibility revealed CVs of 108% between true duplicate measurements and 430% between simulated duplicated measurements.
Local Electrical Function
Figure 3
shows electrical function by unipolar voltage
amplitudes. Normal segments had higher voltage amplitudes (10.9±3.7
mV) than nonviable (4.8±2.1 mV) and viable (8.1±3.1 mV) dysfunctional
segments. On average, viable segments also had higher voltages than
nonviable segments, but we noticed considerable overlap between these 2
groups. Optimum nominal discriminatory value between nonviable and
viable dysfunctional myocardium was 6.5 mV at a sensitivity
and specificity of 69%
(Figure 4
).
|
|
Analysis of reproducibility revealed a CV of 5.8% between true duplicate measurements and 26.9% between simulated duplicate measurements. The corresponding critical difference required for 95% significance of difference between 2 measurements of unipolar voltage was 2.1 and 5.9 mV, respectively.
Between-patient variability was the main component
responsible for the large variability (between-patient component of
variability, 17.9; within-patient variability, 9.6%; F=41.8;
P<0.01). Consequently, each
patient had his own individual level for electrical activity
(Figure 5
). We identified a statistically significant
correlation between the number of nonviable segments and average
voltage amplitude in normal segments
(r=0.55,
P<0.01).
|
Normalized electrical unipolar amplitudes are shown in
Figure 6
. Optimum discriminatory value between nonviable and
viable dysfunctional myocardium was 68% of the values
observed in normal segments
(Figure 7
). Sensitivity and specificity were significantly
higher than the sensitivity and specificity obtained with nominal
discriminatory values (78% versus 69%,
P<0.02;
Figure 8
). Positive and negative predictive values were also
higher with normalized compared with nominal discriminatory values
(Table 2
). Normalized data could not be obtained in 5
patients (16%) because we were unable to identify segments with normal
contraction.
|
|
|
|
We found no regional differences in nominal and normalized
voltage amplitudes within normal, nonviable, or viable segments
(Table 1
).
Procedural Complications
One patient had a hemorrhagic pericardial effusion in
relation to the mapping procedure and was treated with
pericardiocentesis. The patient suffered no permanent
injury.
| Discussion |
|---|
|
|
|---|
Local Contractile Function
Calculation of LS is based on an algorithm creating a
linear LS map. LS describes the shortening of the length of a line
joining any 2 points in the map. All the points surrounding a
particular point, p, are used in the calculation. A weighting function
takes into account the density of points surrounding p, the LV volume,
and the distance of each point from p. The motion of each endocardial
point is a summary of a complex series of motion describing that the
distance between neighboring endocardial points in a normally
contracting region decreases during systole as a result of segmental
shortening of the contracting muscle but does not in noncontracting
segments. Because the CV on duplicate measurements was very high, our
results show that in its present form the algorithm is not optimal
for calculation of local contractile function in enlarged LVs with
globally impaired function. This is in contrast to the findings in
patients with angina and specified regions of the LV with viable or
nonviable ischemia causing local dysfunction but preserved
global LV function.8 The
difference may reflect inherent limitations of the algorithm for
calculation of LS because the points used in the calculation are not
independent variables. Furthermore, inclusion of the enlarged LV
volume in the calculation can affect accuracy of the LS estimate. Even
so, visual qualitative inspection of the color-coded mechanical maps
appears to be useful for identification of dysfunctional regions
because a general reduction in LS in anatomically well-defined regions
separates dysfunctional areas from normally contracting areas despite a
wide scatter of LS values.
Electrical Function in Dysfunctional
Myocardium
The low CV of duplicate unipolar voltage measurements
and the corresponding critical value of only 2.1 mV make the
electroanatomic measurement suitable for detection of viability.
However, unipolar voltage amplitudes display a wide scatter even in
segment with preserved contractile function. Most of the total
variation on unipolar voltage measurements is explained by the
between-subject variation. Myocardial infarction and subsequent
remodeling create altered
electrophysiological
properties.14 Unipolar
voltage has a significant far-field component. Because we could
demonstrate a correlation between the amount of nonviable dysfunctional
tissue and the voltage amplitude in normal segments, we suggest that
individual differences depending on heart size, wall thickness, and
extent of ischemic and infarcted tissue account for the wide
scatter.
The large overlap between segments with normal function and segments with nonviable and viable dysfunction makes it impossible to identify exact nominal discriminatory values for each specific condition. Our data show that individual cutoff levels of electrical activity are more accurate for detection of viable dysfunctional myocardium than a general nominal cutoff level. Depending on the threshold chosen for viability, sensitivity and specificity vary. A low threshold ascertains a high sensitivity so that almost all patients with viable dysfunctional myocardium are identified. A high threshold secures a better specificity so that false-positive results are avoided.
Dysfunctional myocardium most frequently
comprises a mixture of fibrous tissue and viable
myocardium.15
Electrical signals from chronically dysfunctional
myocardium decrease in proportion to the amount of fibrous
tissue.16 Similarly, there
is a significant correlation between severity of tissue fibrosis and
mechanical recovery.17 The
threshold amount of fibrosis that differentiates myocardium
with postoperative improvement from that without is
35%,17 implicating that
65% viable myocytes are necessary to ensure beneficial effect on
contractile function. We suggest that our observation that a 68%
preservation of electrical activity predicts functional recovery merely
reflects the presence of viable myocytes in that order of
magnitude.
Clinical Implications
At present, myocardial viability in patients with
LV dysfunction is assessed by noninvasive myocardial imaging modalities
such as nuclear scintigraphy, PET, and stress
echocardiography. Electroanatomic mapping offers
online detection of myocardial viability in the
catheterization laboratory. Despite its invasive
nature, it appears to be associated with few but potentially serious
complications. Mapping time is modest. The advantage is that it may
enable detection of myocardial viability of dysfunctional
myocardium in immediate continuation of coronary
angiography.
Until now, electromechanical mapping has been evaluated mostly in patients with ischemic heart disease and preserved global LV function. The technique is required only in patients with impaired global LV function resulting from regional myocardial dysfunction. Although assessment of local mechanical dysfunction may not be optimal in these patients, the system enables precise anatomical reconstruction of the LV.7 13 Its combination with measurement of local endocardial ECG amplitudes enables the construction of electroanatomic maps that appear to identify viable myocardial regions as accurately as stress echocardiography and SPECT.18 The technology may therefore become a single determinant of viability.
Study Limitations
The main limitation of the present study is the
lack of follow-up to clarify whether segments classified as nonviable
or viable are truly nonviable or viable after
revascularization. We chose comparison with PET for
this investigation because measurement of perfusion and myocardial FDG
uptake by PET is considered the gold standard for assessment of
myocardial viability in patients with ischemic heart disease. A
limitation created by the use of normalized values for assessment of
electrical activity is that a few patients may not have segments with
preserved contractility; therefore, normalization is
not possible.
Despite our efforts to define the boundaries of the LV for comparative analysis of mapping, echocardiography, and PET, we cannot be sure that we have identified completely identical anatomic areas by the 3 methods. The overall concordance between LV volumes determined by mapping and echocardiography indicates that the alignment is reasonable.
Conclusions
Electroanatomic mapping may enable identification of
myocardial viability. However, endocardial ECG amplitudes display wide
scatter, complicating the establishment of exact nominal values that
allow distinction between viable and nonviable areas. Individual
normalization of unipolar voltage amplitudes improves
diagnostic accuracy of electroanatomic mapping for
detection of viable dysfunctional
myocardium.
| Acknowledgments |
|---|
Received August 23, 2000; revision received November 21, 2000; accepted December 7, 2000.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J. L. Huang, C.-T. Tai, Y.-J. Lin, B.-H. Huang, K.-T. Lee, S. Higa, Y. Yuniadi, Y.-J. Chen, S.-L. Chang, L.-W. Lo, et al. Substrate Mapping to Detect Abnormal Atrial Endocardium With Slow Conduction in Patients With Atypical Right Atrial Flutter J. Am. Coll. Cardiol., August 1, 2006; 48(3): 492 - 498. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gyongyosi, A. Khorsand, S. Zamini, W. Sperker, C. Strehblow, J. Kastrup, E. Jorgensen, B. Hesse, K. Tagil, H. E. Botker, et al. NOGA-Guided Analysis of Regional Myocardial Perfusion Abnormalities Treated With Intramyocardial Injections of Plasmid Encoding Vascular Endothelial Growth Factor A-165 in Patients With Chronic Myocardial Ischemia: Subanalysis of the EUROINJECT-ONE Multicenter Double-Blind Randomized Study Circulation, August 30, 2005; 112(9_suppl): I-157 - I-165. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kastrup, E. Jorgensen, A. Ruck, K. Tagil, D. Glogar, W. Ruzyllo, H. E. Botker, D. Dudek, V. Drvota, B. Hesse, et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris: A randomized double-blind placebo-controlled study: The Euroinject One trial J. Am. Coll. Cardiol., April 5, 2005; 45(7): 982 - 988. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Samady, C. J. Choi, M. Ragosta, E. R. Powers, G. A. Beller, and C. M. Kramer Electromechanical Mapping Identifies Improvement in Function and Retention of Contractile Reserve After Revascularization in Ischemic Cardiomyopathy Circulation, October 19, 2004; 110(16): 2410 - 2416. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Graf, M. Gyongyosi, A. Khorsand, S. G. Nekolla, C. Pirich, K. Kletter, R. Dudczak, D. Glogar, G. Porenta, and H. Sochor Electromechanical Properties of Perfusion/Metabolism Mismatch: Comparison of Nonfluoroscopic Electroanatomic Mapping with 18F-FDG PET J. Nucl. Med., October 1, 2004; 45(10): 1611 - 1618. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kawamoto, T. Murayama, K. Kusano, M. Ii, T. Tkebuchava, S. Shintani, A. Iwakura, I. Johnson, P. von Samson, A. Hanley, et al. Synergistic Effect of Bone Marrow Mobilization and Vascular Endothelial Growth Factor-2 Gene Therapy in Myocardial Ischemia Circulation, September 14, 2004; 110(11): 1398 - 1405. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Vahlhaus, H.-J. Bruns, J. Stypmann, T. D.T Tjan, F. Janssen, M. Schafers, H. H Scheld, O. Schober, G. Breithardt, and T. Wichter Direct epicardial mapping predicts the recovery of left ventricular dysfunction in chronic ischaemic myocardium Eur. Heart J., January 2, 2004; 25(2): 151 - 157. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Wiggers, H. E. Botker, P. Sogaard, A. Kaltoft, F. Hermansen, W. Y. Kim, L. Krusell, and L. Thuesen Electromechanical mapping versus positron emission tomography and single photon emission computed tomography for the detection of myocardial viability in patients with ischemic cardiomyopathy J. Am. Coll. Cardiol., March 5, 2003; 41(5): 843 - 848. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kawamoto, T. Tkebuchava, J.-I. Yamaguchi, H. Nishimura, Y.-S. Yoon, C. Milliken, S. Uchida, O. Masuo, H. Iwaguro, H. Ma, et al. Intramyocardial Transplantation of Autologous Endothelial Progenitor Cells for Therapeutic Neovascularization of Myocardial Ischemia Circulation, January 28, 2003; 107(3): 461 - 468. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Kornowski Left ventricular electromechanical mapping for determination of myocardial function and viability J. Am. Coll. Cardiol., September 18, 2002; 40(6): 1075 - 1078. [Full Text] [PDF] |
||||
![]() |
E. C. Perin, G. V. Silva, R. Sarmento-Leite, A. L.S. Sousa, M. Howell, R. Muthupillai, B. Lambert, W. K. Vaughn, and S. D. Flamm Assessing Myocardial Viability and Infarct Transmurality With Left Ventricular Electromechanical Mapping in Patients With Stable Coronary Artery Disease: Validation by Delayed-Enhancement Magnetic Resonance Imaging Circulation, August 20, 2002; 106(8): 957 - 961. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |